araag2/HINT huggingface dataset:
Clinical trial NCT00053807 (phase 3, status: completed)
Conditions: kidney cancer
ICD codes: D17.71, D30.00, D30.01, D30.02, D41.00, D41.01, D41.02
Drugs: fluorouracil
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed primary renal cell carcinoma meeting 1 of the following
             criteria:

               -  Stage T3b, T3c, or T4 tumor

               -  Any pT stage and nodal status pN 1 or 2

               -  Any pT stage and microscopic positive margins

               -  Presence of any microscopic vascular invasion

          -  Underwent surgical resection of primary tumor within the past month

               -  Removal of clinical N+ disease required

          -  No evidence of metastatic disease

          -  No evidence of macroscopic residual disease

        PATIENT CHARACTERISTICS:

        Age

          -  75 and under

        Performance status

          -  WHO 0-1

        Life expectancy

          -  Not specified

        Hematopoietic

          -  WBC at least 3,500/mm^3

          -  Platelet count at least 100,000/mm^3

        Hepatic

          -  Liver function tests no greater than 1.25 times upper limit of normal (ULN)

        Renal

          -  Creatinine less than 1.5 times ULN

        Cardiovascular

          -  No myocardial infarction within the past 6 months

          -  No unstable angina pectoris

        Other

          -  Not pregnant or nursing

          -  No prior or other concurrent malignancies that would preclude study therapy or
             comparisons

          -  No other concurrent illness that would preclude study therapy

          -  No concurrent active infections requiring antibiotic therapy

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  No other concurrent immunotherapy

        Chemotherapy

          -  No prior chemotherapy

        Endocrine therapy

          -  No concurrent corticosteroids

          -  No concurrent hormonal therapy

        Radiotherapy

          -  No prior radiotherapy

        Surgery

          -  See Disease Characteristics

          -  No prior major organ allografts

        Other

          -  No other concurrent investigational drugs, agents, or devices
Clinical trial NCT01359813 (phase 3, status: terminated)
Conditions: cirrhosis, sepsis, renal failure
ICD codes: K74.3, K74.4, K74.5, K74.60, K74.69, P78.81, K70.30, A02.1, A22.7, A26.7, A32.7, A42.7, A54.86, B37.7, P96.0, O03.32, O04.82, O08.4, O03.82, O07.32, I13.11
Drugs: human albumin
SMILES: CC1=CC(O)=CC(C)=C1Cl
Reason stopped: 
    decision of independent monitoring committee:risk of death at 3 months higher in albumin group
    than in control group, without reaching significance level.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Cirrhosis defined by clinical, laboratory or ultrasonographic findings

          -  Child-Pugh > 8

          -  Sepsis defined by the presence of proved or suspected infection with two of the four
             SIRS (systemic inflammatory response syndrome) criteria (Wong F, et al. Sepsis in
             cirrhosis: report on the 7th meeting of the international ascites club. Gut 2005)

          -  Creatinine < 160 µmol/L

          -  Written informed consent

          -  Absence of the exclusion criteria

        Exclusion Criteria:

          -  Spontaneous bacterial peritonitis

          -  Difficult to treat infections such as : endocarditis, septic arthritis, osteomyelitis

          -  Heart insufficiency (YHA III-IV)

          -  Digestive bleeding during the week preceding the study

          -  Septic shock

          -  Hepatocellular carcinoma : stage D

          -  Use of antibiotics during the week preceding the study, except noroxin used for
             long-term antibioprophylaxy

          -  Diseases which can influence the short term survival
Clinical trial NCT01323478 (phase 3, status: completed)
Conditions: major depressive disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: vortioxetine (lu aa21004)
SMILES: CC1=CC=C(SC2=CC=CC=C2N2CCNCC2)C(C)=C1
Eligibility criteria:

        Inclusion Criteria:

        Patients who completed 8-week short-term treatment study, 13267A (NCT01140906), for Major
        Depressive Episode immediately prior to enrolment in this extension study

        Exclusion Criteria:

          -  Any current psychiatric disorder other than MDD as defined in the Diagnostic and
             Statistical Manual of Mental Disorders, 4th edition, Text Revision (DSM-IV TR)

          -  Female patients of childbearing potential who are not using effective contraception

          -  Use of any psychoactive medication

          -  The patient, in the investigator's clinical judgment, has a significant risk of
             suicide.

        Other protocol-defined inclusion and exclusion criteria applied.
Clinical trial NCT00003376 (phase 3, status: completed)
Conditions: bladder cancer, transitional cell cancer of the renal pelvis and ureter, urethral cancer
ICD codes: D30.3, C67.5, C67.9, C79.11, C67.0, C67.1, D41.4
Drugs: carboplatin, cisplatin, doxorubicin hydrochloride, methotrexate, paclitaxel, vinblastine
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        DISEASE CHARACTERISTICS: Histologically confirmed transitional cell carcinoma of the
        urothelium (renal pelvis, ureter, bladder, or urethra) or mixed histologies containing a
        component of transitional cell carcinoma of the urothelium with manifestations of
        progressing regional or metastatic cancer Clinically unsuspected organ-confined prostate
        cancer found during cystoprostatectomy allowed Evaluable or measurable disease No
        significant pericardial or pleural effusion or edema No significant ascites No CNS
        metastases

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: Not
        specified Hematopoietic: Granulocyte count at least 1,500/mm3 Platelet count at least
        100,000/mm3 Hepatic: AST no greater than 2 times upper limit of normal Bilirubin no greater
        than 1.5 mg/dL Renal: Creatinine no greater than 1.7 mg/dL Cardiovascular: No history of
        severe cardiovascular disease (American Heart Association class III or IV), uncontrolled
        congestive heart failure, or cardiac dysrhythmias Other: Prior malignancy allowed if
        curatively treated with no evidence of recurrence No active infection requiring parenteral
        antibiotics Not pregnant or nursing Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior systemic biologic response modifier
        therapy No concurrent filgrastim (G-CSF) within 24 hours prior to and after study
        chemotherapy administration Chemotherapy: No prior systemic chemotherapy Endocrine therapy:
        Not specified Radiotherapy: No prior pelvic radiotherapy as a component of bladder-sparing
        therapy or as an adjuvant for locally advanced disease with positive margins No concurrent
        local radiotherapy for pain control or life-threatening situations Surgery: See Disease
        Characteristics
Clinical trial NCT00500409 (phase 3, status: completed)
Conditions: osteoporosis
ICD codes: M81.6, Z82.62, Z13.820, M81.8, Z87.310, M81.0, M80.80XS
Drugs: osteoform, shelcal
SMILES: [Ca]
Eligibility criteria:

        Inclusion Criteria:

        Postmenopausal women with osteoporosis (Lumbar spine or femoral neck BMD or total hip
        T-score less than or equal to-2.5)

        Exclusion Criteria:

          1. Women with vertebral (L1-L4) abnormalities that preclude accurate measurement by DEXA.

          2. Women on medications that are known to affect bone for more than 7 days in the past 6
             months.

          3. Currently taking systemic prednisone, inhaled steroids, anticoagulants,
             anticonvulsants.

          4. History of rhPTH use or known hypersensitivity to study drug.

          5. Vitamin D3 deficiency (Vitamin D3 < 20 ng/ml).

          6. Abnormal thyroid function.

          7. History of kidney disease.

          8. Any history of hypercalciuria, hypercalcemia or hyperparathyroidism.

          9. History of active or treated tuberculosis or significant liver disease or
             gastrointestinal disease or cancer.
Clinical trial NCT00943709 (phase 3, status: withdrawn)
Conditions: hyperglycemia, leukemia
ICD codes: R73.9, E10.65, E11.65, E13.65, E08.65, E09.65, C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01
Drugs: therapeutic insulin
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O
Reason stopped: 
    lack of accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed acute myeloid leukemia or acute lymphoid leukemia

               -  Newly diagnosed or relapsed disease

          -  Undergoing induction or salvage chemotherapy treatment

          -  Must demonstrate 2 random blood sugars of ≥ 140 mg/dL while on total parenteral
             nutrition (TPN) OR 2 preprandial sugars of ≥ 140 mg/dL if patient is not on TPN

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-3

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Prior diagnosis of diabetes mellitus allowed

          -  No known history of an allergy to insulin

          -  No documented active infection

        PRIOR CONCURRENT THERAPY:

          -  Concurrent corticosteroids allowed

          -  No concurrent oral hypoglycemic agents
Clinical trial NCT00325910 (phase 3, status: terminated)
Conditions: diabetes mellitus, type 2, heart failure, congestive
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44, I50.20, I50.21, I50.22, I50.30, I50.31, I50.32, I50.40
Drugs: metformin
SMILES: CSCC[C@H](N)C(O)=O
Reason stopped: 
    insufficient study participants
  
Eligibility criteria:

        Inclusion Criteria:

          -  All subjects with physician-diagnosed symptomatic heart failure (NYHA class I, II,
             III, IV) and type 2 diabetes.

        A diagnosis of type 2 diabetes defined as:

          -  a previous physician diagnosis of type 2 diabetes as documented in the subject's
             clinical record or;

          -  receiving oral antihyperglycemic agents or;

          -  a new diagnosis of type 2 diabetes during the visit within the heart failure clinic or
             hospital based on a fasting blood glucose ≥7.0 mmol/L or random blood glucose ≥11.1
             mmol/L accompanied by acute metabolic decompensation or 2 hour plasma glucose in a 75
             gram oral glucose tolerance test ≥11.1 mmol/L.

        Exclusion Criteria:

          -  subjects currently receiving greater than 1500 mg of metformin therapy per day

          -  subjects who are unwilling to change their antidiabetic regimens;

          -  subjects receiving insulin therapy;

          -  serum creatinine ≥ 180 μmol/L;

          -  A1c < 7.0 percent;

          -  inability to communicate (language barrier);

          -  dementia/mental illness;

          -  age < 18 years;

          -  subjects unwilling to complete self-monitoring of serum blood sugars during the trial
             period.

          -  those participating in another heart failure or diabetes clinical trial involving
             medication;

          -  severe comorbidities or foreshortened life expectancy;

          -  subjects who do not provide written informed consent to participate.
Clinical trial NCT01006980 (phase 3, status: completed)
Conditions: malignant melanoma
ICD codes: C43.0, C43.31, C43.51, C43.9, C43.4, C43.52, C43.10
Drugs: vemurafenib, dacarbazine
SMILES: CCCS(=O)(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1, N1C=CN=C1
Eligibility criteria:

        Inclusion Criteria:

          -  adults, >/=18 years of age

          -  metastatic melanoma, stage IIIC or IV (AJCC)

          -  treatment-naïve (no prior systemic anticancer therapy)

          -  positive for BRAF V600E mutation

          -  measurable disease by RECIST criteria

          -  negative pregnancy test and, for fertile men and women, effective contraception during
             treatment and for 6 months after completion

        Exclusion Criteria:

          -  active central nervous system metastases

          -  history of carcinomatous meningitis

          -  severe cardiovascular disease within 6 months prior to study drug administration

          -  previous malignancy within 5 years prior to study, except for basal or squamous cell
             carcinoma of the skin, melanoma in-situ, or carcinoma in-situ of the cervix
Clinical trial NCT00486811 (phase 3, status: completed)
Conditions: pain, knee osteoarthritis
ICD codes: N50.82, R07.2, R07.82, R10.13, R10.33, R14.1, R52, M17.9, M17.0, M17.10, M17.11, M17.12, M17.2, M17.30
Drugs: tapentadol er (100 to 250 mg twice daily), matching placebo (twice daily), oxycodone cr (20 to 50 mg twice daily)
SMILES: CC[C@H]([C@@H](C)CN(C)C)C1=CC(O)=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC(=O)OC1=CC=CC=C1C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients diagnosed with osteoarthritis of the knee based on the American College of
             Rheumatology (ACR) criteria and functional capacity class of I- III;

          -  Patients taking analgesic medications for at least 3 months prior to screening and
             dissatisfied with their current therapy;

          -  Patients requiring opioid treatment must be taking daily doses of opioid- based
             analgesic, equivalent to <160 mg of oral morphine;

          -  Baseline score of >=5 on an 11-point numeric rating scale, calculated as the average
             pain intensity during the last 3 days prior to randomization.

        Exclusion Criteria:

          -  History of alcohol and/or drug abuse in Investigator's judgment;

          -  Chronic hepatitis B or C, or HIV, presence of active hepatitis B or C within the past
             3 months;

          -  Life-long history of seizure disorder or epilepsy;

          -  History of malignancy within past 2 years, with exception of basal cell carcinoma that
             has been successfully treated;

          -  Uncontrolled hypertension;

          -  Patients with severely impaired renal function;

          -  Patients with moderate to severely impaired hepatic function or with laboratory values
             reflecting inadequate hepatic function,

          -  Treatment with neuroleptics, monoamine oxidase inhibitors, serotonin norepinephrine
             reuptake inhibitors (SNRI), tricyclic antidepressants, anticonvulsants, or
             anti-parkinsonian drugs, treatment with any other analgesic therapy than
             investigational medication or rescue medication during the trial.
Clinical trial NCT00475969 (phase 3, status: completed)
Conditions: anxiety
ICD codes: F41.1, F41.9, F40.8, F40.9, F41.3, F41.8, F43.22
Drugs: duloxetine, placebo
SMILES: CN(C)CCC[C@]1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male and female outpatients at least 18 years of age presenting with generalized
             anxiety disorder (GAD) based on the disease diagnostic criteria The patient must
             suffer from GAD and not from an adjustment disorder or anxiety disorder not otherwise
             specified (NOS). Symptoms of GAD should not be situational in nature.

          -  Females of childbearing potential (not surgically sterilized and between menarche and
             1 year postmenopause) who are not breastfeeding; test negative for pregnancy at the
             time of enrollment based on a urine pregnancy test; and agree to use a reliable method
             of birth control during the study and for 1 week following the last dose of study
             drug.

          -  Must have a Clinical Global Impressions of Severity (CGI-Severity) score of greater
             than or equal to 4 at Visit 1 and Visit 2.

          -  At Visit 1, patient must have a Covi Anxiety Scale (CAS) score of greater than or
             equal to 9, no item in the Raskin Depression Scale (RDS) may be greater than 3, and
             the CAS must be greater than the RDS.

          -  Must have a Hospital Anxiety and Depression Scale (HADS) anxiety subscale score of
             greater than or equal to 10 at Visit 1.

        Exclusion Criteria:

          -  Any current and primary DSM-IV Axis I diagnosis other than GAD.

               -  Patients diagnosed with or who have a history of major depressive disorder (MDD)
                  within the past 6 months or

               -  Patients diagnosed with or who have a history of Panic Disorder, Post-Traumatic
                  Stress Disorder (PTSD), or an eating disorder within the past year or

               -  Patients who have been diagnosed with Obsessive Compulsive Disorder (OCD),
                  Bipolar Affective Disorder, psychosis, factitious disorder, or somatoform
                  disorders during their lifetime.

          -  The presence of an Axis II disorder or history of antisocial behavior, which, in the
             judgment of the investigator, would interfere with compliance with the study protocol.

          -  Benzodiazepine use 14 days prior to Visit 2.

          -  Patients judged clinically to be at serious suicidal risk, or patients who, in the
             opinion of the investigator, are poor medical or psychiatric risks for study
             completion.

          -  Have received treatment within the last 30 days with a drug (not including study drug)
             that has not received regulatory approval for any indication at the time of study
             entry.
Clinical trial NCT01453855 (phase 3, status: completed)
Conditions: open-angle glaucoma, ocular hypertension
ICD codes: H40.10X0, H40.10X1, H40.10X2, H40.10X3, H40.10X4, H40.1130, H40.1131, H40.053, H40.051, H40.052, H40.059
Drugs: travoprost ophthalmic solution, 0.003%, travoprost ophthalmic solution, 0.004%
SMILES: CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(=C1)C(F)(F)F, CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(=C1)C(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of open-angle glaucoma (including open-angle glaucoma with pseudoexfoliation
             or pigment dispersion) or ocular hypertension.

          -  Qualifying intraocular pressure at both eligibility visits.

          -  Understand and sign an informed consent form.

          -  Other protocol-defined inclusion criteria may apply.

        Exclusion Criteria:

          -  Women of childbearing potential if pregnant, breast-feeding, or not on adequate birth
             control.

          -  Severe central visual field loss in either eye.

          -  Chronic, recurrent or severe inflammatory eye disease.

          -  Best corrected visual acuity (BCVA) score worse than 55 ETDRS letters (equivalent to
             20/80 Snellen).

          -  Any abnormality preventing reliable applanation tonometry.

          -  Hypersensitivity to prostaglandin analogs or to any component of the study
             medications.

          -  Therapy with another investigational agent within 30 days prior to the Screening
             Visit.

          -  Other protocol-defined exclusion criteria may apply.
Clinical trial NCT00345644 (phase 3, status: completed)
Conditions: osteoporosis
ICD codes: M81.6, Z82.62, Z13.820, M81.8, Z87.310, M81.0, M80.80XS
Drugs: risedronate, risedronate placebo
SMILES: OC(CC1=CN=CC=C1)(P(O)(O)=O)P(O)(O)=O, OC(CC1=CN=CC=C1)(P(O)(O)=O)P(O)(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Osteopenic, postmenopausal women, between 55 and 75 years of age with a body mass
             index (BMI) < 30 kg/m²

        Exclusion Criteria:

          -  Clinical or radiological evidence of osteoporosis

          -  Severe renal impairment

          -  Serum 5-hydroxy vitamin D level < 15 ng/ml

          -  History of recent primary hyperparathyroidism or recent thyroid disorder

          -  History of any generalized bone disease

          -  Current use of glucocorticoids, estrogens, progestins, calcium supplements > 1 g/day,
             vitamin D supplements > 800 IU/day, parathyroid hormone (PTH), or any bisphosphonate
             for > 1 month at any time within the past 6 months.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
Clinical trial NCT00163462 (phase 3, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: ciclesonide
SMILES: [H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(O[C@@H](O2)C1CCCCC1)C(=O)COC(=O)C(C)C
Eligibility criteria:

        Main Inclusion Criteria:

          -  History of persistent bronchial asthma for at least 6 months

          -  FEV1 50-90% of predicted

        Main Exclusion Criteria:

          -  Concomitant severe diseases or diseases which are contraindications for the use of
             inhaled steroids

          -  COPD (chronic bronchitis or emphysema) and/or other relevant lung diseases causing
             alternating impairment in lung function

          -  Respiratory tract infection or asthma exacerbation within the last 30 days prior to
             entry into the study

          -  History of life-threatening asthma

          -  Premature birth

          -  Current smoking

          -  Smoking history with either equal or more than 10 pack-years

          -  Pregnancy

          -  Intention to become pregnant during the course of the study

          -  Breast feeding

          -  Lack of safe contraception